United States Patent and Trademark Office (USPTO) Grants Evoke Pharma a Formulation Patent Covering GIMOTI Read more about United States Patent and Trademark Office (USPTO) Grants Evoke Pharma a Formulation Patent Covering GIMOTI
Evoke Pharma Receives Notice of Allowance from USPTO for GIMOTI-Related Patent Read more about Evoke Pharma Receives Notice of Allowance from USPTO for GIMOTI-Related Patent
Evoke Pharma & EVERSANA Announce Compelling Real-World Data on the Impact of GIMOTI in Reducing the Utilization of Healthcare Resources to be Presented at the Academy of Managed Care Pharmacy (AMCP) 2023 Read more about Evoke Pharma & EVERSANA Announce Compelling Real-World Data on the Impact of GIMOTI in Reducing the Utilization of Healthcare Resources to be Presented at the Academy of Managed Care Pharmacy (AMCP) 2023
Evoke Pharma Reports Fourth Quarter and Full Year 2022 Financial Results Read more about Evoke Pharma Reports Fourth Quarter and Full Year 2022 Financial Results
Evoke Pharma to Report Fourth Quarter and Full Year 2022 Results on March 21, 2023 Read more about Evoke Pharma to Report Fourth Quarter and Full Year 2022 Results on March 21, 2023
Evoke Pharma and EVERSANA Selected to Present Results of Real-World Healthcare Utilization Study Comparing GIMOTI® and Oral Metoclopramide at the Digestive Disease Week Plenary Session Read more about Evoke Pharma and EVERSANA Selected to Present Results of Real-World Healthcare Utilization Study Comparing GIMOTI® and Oral Metoclopramide at the Digestive Disease Week Plenary Session
Evoke Announces Teva Ends Pursuit of Paragraph IV ANDA Against Gimoti Read more about Evoke Announces Teva Ends Pursuit of Paragraph IV ANDA Against Gimoti
Evoke Pharma Announces Acceptance of an Abstract at the Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2023 Read more about Evoke Pharma Announces Acceptance of an Abstract at the Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2023
USPTO Grants New Patent to Evoke Pharma Covering the Usage of GIMOTI® To Treat Moderate to Severe Gastroparesis Read more about USPTO Grants New Patent to Evoke Pharma Covering the Usage of GIMOTI® To Treat Moderate to Severe Gastroparesis
Evoke Pharma Strengthens its Intellectual Property Portfolio with a Notice of Allowance from the USPTO for a Patent Application Related to GIMOTI® Read more about Evoke Pharma Strengthens its Intellectual Property Portfolio with a Notice of Allowance from the USPTO for a Patent Application Related to GIMOTI®